Lee Chung Un, Chung Jae Hoon, Song Wan, Kang Minyong, Sung Hyun Hwan, Jeong Byong Chang, Seo Seong Il, Jeon Seong Soo, Lee Hyun Moo, Jeon Hwang Gyun
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Prostate Int. 2022 Mar;10(1):56-61. doi: 10.1016/j.prnil.2021.08.003. Epub 2021 Sep 8.
We investigated the necessity of multiple core biopsies when performing transperineal template-guided mapping biopsy (TTMB) for patients with large prostates and no suspicious lesions on multiparametric magnetic resonance imaging (mpMRI).
We retrospectively analyzed 304 patients on active surveillance (AS), 212 patients with previously negative transrectal ultrasound-guided biopsy (TRUS-Bx) and 67 biopsy naïve patients who underwent TTMB between May 2017 and December 2020. The number of core biopsies and acute urinary retention (AUR) rates were analyzed in relation to the prostate volume (PV). Cancer detection rate according to the prostate volume and Prostate Imaging-Reporting and Data System (PI-RADS) scores were compared using the Pearson Chi-square test.
AUR occurred more frequently in patients with PV over 39 cc (5.5% vs. 24.4%, < 0.001). In addition, incidence of AUR was more in patients with PV over 39 cc and PI-RADS score of 1-2 on mpMRI (3.7% vs. 22.2%, < 0.001). There was no significant difference in the detection rates of any prostate cancer or clinically significant prostate cancer (csPCA) between the patients on AS with PV < 39 cc and PV ≥ 39 cc and PI-RADS score 1-2 (57.4% vs. 50%, = 0.507; 17% vs. 8.8%, = 0.412, respectively). Additionally, no significant difference was found in the detection rates of any prostate cancer or csPCA between the patients with PV < 39 cc and PV ≥ 39 cc and PI-RADS score 1-2 who either had a previously negative TRUS-Bx or were biopsy naïve (27.9% vs. 16.2%, = 0.101, 8.2% vs. 4.1%, = 0.31, respectively).
Increasing the number of core biopsies of prostates measuring ≥39 cc with PI-RADS 1-2 on mpMRI does not significantly increase the detection rates of any prostate cancer or csPCA.
我们研究了在对前列腺体积较大且多参数磁共振成像(mpMRI)上无可疑病变的患者进行经会阴模板引导穿刺活检(TTMB)时,多点穿刺活检的必要性。
我们回顾性分析了2017年5月至2020年12月期间接受TTMB的304例接受主动监测(AS)的患者、212例先前经直肠超声引导活检(TRUS - Bx)结果为阴性的患者以及67例未接受过活检的患者。分析了穿刺活检的针数与急性尿潴留(AUR)发生率与前列腺体积(PV)的关系。使用Pearson卡方检验比较了根据前列腺体积和前列腺影像报告和数据系统(PI - RADS)评分的癌症检出率。
前列腺体积超过39 cc的患者中AUR更频繁发生(5.5%对24.4%,P < 0.001)。此外,mpMRI上前列腺体积超过39 cc且PI - RADS评分为1 - 2的患者中AUR发生率更高(3.7%对22.2%,P < 0.001)。在AS患者中,前列腺体积<39 cc与≥39 cc且PI - RADS评分为1 - 2的患者之间,任何前列腺癌或临床显著前列腺癌(csPCA)的检出率无显著差异(分别为57.4%对50%,P = 0.507;17%对8.8%,P = 0.412)。此外,在前列腺体积<39 cc与≥39 cc且PI - RADS评分为1 - 2的患者中,无论是先前TRUS - Bx结果为阴性还是未接受过活检的患者,任何前列腺癌或csPCA的检出率也无显著差异(分别为27.9%对16.2%,P = 0.101;8.2%对4.1%,P = 0.31)。
对于mpMRI上PI - RADS为1 - 2且前列腺体积≥39 cc的患者,增加穿刺活检针数并不能显著提高任何前列腺癌或csPCA的检出率。